BVL3572S inhibits HisC and AlaA, exploiting vitamin B6 dependency to kill Mycobacterium tuberculosis.

Zainab Edoo Astrid Lenne-Delmotte C. Grosse Marie Devaere Marion Michel G. Caron Ernesto Anoz-Carbonell Kamel Djaout Rosangela Frita C. Gaudin Line Hofmann Sophie Lecher Véronique Megalizzi A. Michelotti D. Rengel Pauline Rouan S. Slupek L. Tawk R. Antoine Hanna Kulyk Glenn E. Dale C. Guilhot N. Willand G. Lippens R. Wintjens Alain R. Baulard

Aug 2026 · Cell Chemical Biology · 0 citations

Medicine

TL;DR

These findings establish BVL3572S as a promising lead compound acting through a previously unexploited, multitarget mechanism, and display strong synergy with the antitubercular drug D-cycloserine.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

The Dephospho-CoA Kinase of Mycobacterium tuberculosis: Molecular Mechanism and Function.

The found that the S15A, R145A or N175A mutants showed markedly reduced activity, whereas the K14A mutation completely abolished activity, and deletion of residues 27-101 (Δ27-101) led to a significant loss of function.

Da-Feng Liu, Hua-Shui Deng, Hong-Jun Song · ACS Omega · 0 citations

Aug 2026

Molecular insights into inhibitor action on the catalytic activity of Mycobacterium tuberculosis cystathionine β-synthase enzyme.

These findings provide a mechanistic rationale for MtbCBS inhibition, and the unexplored roles of these key residues can be considered in the design of next-generation inhibitors targeting CBS enzymes implicated in infectious diseases, cancer, and neurological disorders.

Sainath Polepalli, Anupam Roy, Bapan Mondal et al. · International Journal of Bio... · 0 citations

Open access Sep 2026

Discovery of new diaminoquinazolines against Mycobacterium tuberculosis: chemical synthesis and in vitro evaluation

Despite the availability of multiple treatment options, the emergence of drug-resistant Mycobacterium tuberculosis (Mtb) strains presents a significant health concern worldwide. This necessitates the development of novel antitubercular agents with distinct mechanisms of action. Diaminoquinazolines (DAQs) have demonstra...

Mukul Kore, N. Sundaramoorthy, Saqib Kidwai et al. · RSC Advances · 0 citations

Open access Sep 2026

The Flexible Peripheral Segments Modulate the Catalytic Activity of the FAD-Containing Monooxygenase EthA from Mycobacterium tuberculosis

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health concern, particularly due to the emergence of drug-resistant strains. FAD-containing monooxygenase EthA activates the antitubercular prodrug ethionamide (ETH) in Mtb. However, the structural and functional mechanisms of Mtb Eth...

Da-Feng Liu, Xie-Ping Sun, Feng Yu et al. · Biomolecules · 0 citations

Sep 2026

Design, Synthesis, and Antimicrobial Activity of Novel Cyt- bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosis

Drug-resistant Mycobacterium tuberculosis (Mtb) poses a growing threat, necessitating new therapeutic strategies. The cytochrome bcc-aa3 oxidase (Cyt-bcc) is an attractive target, yet single-agent inhibition fails owing to compensation by the alternative cytochrome bd terminal oxidase (Cyt-bd). Herein, we describe a...

Qiao Qin, Zhuo-Heng Liu, Chen-Yi Cheung et al. · ACS Medicinal Chemistry Lett... · 0 citations

Aug 2026

Synthesis, multi-target enzyme inhibition, and in silico evaluation of phthalimide derivatives with relevance to tuberculosis-associated pathophysiology.

A new series of phthalimide derivatives was synthesized and structurally characterized through 1H NMR and 13C NMR, with further optimization performed at the DFT level, identifying C15 and C17 as promising lead compounds for further optimization as multitarget enzyme inhibitors.

A. Khushal, Sara Khan, Umar Farooq et al. · Bioorganic chemistry (Print) · 0 citations